Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.
09 July 2024
09 July 2024
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.
The Association of the British Pharmaceutical Industry (ABPI) also called out Novartis, Pfizer, and Otsuka for breaching its code.
The initial term of the agreement between Moderna and Mitsubishi Tanabe extends until 31 March 2029.
The move grants Ligand royalty rights to QARZIBA (dinutuximab beta), a treatment for high-risk neuroblastoma in patients aged 12 months and above.
Novo Holdings and Abingworth jointly spearheaded the investment round.
The development in Macau follows previous approvals on the Chinese mainland for the same indications.
Used with chloroquine, tafenoquine can effectively treat both stages of the disease.
XPOVIO met the pre-specified primary endpoint of the trial, with patients achieving a centrally assessed overall response rate.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.